Join
Live feed
·
PRReleasevia Quantisnow
Poseida Therapeutics Inc. logo

Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting

ByQuantisnow·Wall Street's wire, on your screen.
PSTX· Poseida Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PSTX (Poseida Therapeutics Inc.) and more on Quantisnow.